Previous phase III clinical trials have demonstrated the prognostic advantage of combined androgen deprivation therapy with bicalutamide and luteinizing hormone-releasing hormone (LH-RH) over LH-RH monotherapy in Japanese patients with locally advanced prostate cancer without metastasis9. The gene discussed is GNRH1; the disease is prostate cancer.